As of March 26, we're $27,100 in the red for the quarter. Donate here to support this vital work
Subscribe here and join over 13,000 subscribers to our free weekly newsletter

Experimental treatment for PTSD: Ecstasy
Key Excerpts from Article on Website of CNN


CNN, December 3, 2012
Posted: December 11th, 2012
http://www.cnn.com/2012/12/01/health/ecstasy-ptsd-1/

More than 7 million Americans suffer from PTSD, and by most estimates, only half of them -- at best -- are ever cured. A decade ago, the widely acknowledged need for better treatments opened the door to [South Carolina psychiatrist Dr. Michael] Mithoefer and his unconventional approach. By ... February 2005, the soft-spoken, ponytailed Mithoefer had managed to convince the Drug Enforcement Administration to green-light a study of Ecstasy as an adjunct to psychotherapy. He'd gotten the 3,4-methylenedioxy-methylamphetamine (MDMA) -- the chemical name for pure Ecstasy -- from Rick Doblin, the founder of a MAPS, the Multidisciplinary Association for Psychedelic Studies. The group's stated purpose is to develop "medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana." It wants to turn mind-altering drugs like Ecstasy into prescription medicine. To win broader acceptance for MDMA -- and for cousins like LSD and psilocybin, the mind-altering compound in so-called magic mushrooms -- "the medical route was the only route. Everything else was blocked." That meant a formal plan for drug development: study protocols, institutional review boards and the rest. Mithoefer, a University of Virginia-trained clinician who specializes in trauma and had a long-running interest in MDMA, was the perfect partner.

Note: To watch a CNN video clip on this showing remarkable success in treating PTSD, click here. For deeply revealing reports from reliable major media sources on beneficial mind-altering drugs, click here.


Latest News


Key News Articles from Years Past